RTA
RTA is a synthetic 36-amino acid triagonist peptide structurally modified with a fatty acid side chain, designed to interact with glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. Supplied as a lyophilized powder in a 3mL vial, it is intended exclusively for in vitro laboratory research by qualified scientific personnel.
This peptide has been utilized in preclinical studies examining triple incretin receptor binding kinetics, hepatic lipid metabolism signaling, pancreatic beta cell function, and multi-pathway energy substrate cycling — independent of the broader hormonal mechanisms associated with endogenous incretin and glucagon activity.
Product Details
- Form: Lyophilized powder (for laboratory research)
- Amounts: 5 mg per vial
- Purity: ≥ 98% (HPLC tested)
- Sequence: 39–amino acid linear peptide analogue (GLP-1/GIP/glucagon triple agonist)
- Molecular Formula: C₂₁₉H₃₄₅N₆₁O₆₅
- Molecular Weight: ~5000 Da (approx.)
- Intended Use: Laboratory research only
DISCLAIMER: This product is strictly to be used for scientific research use only. It is not for human consumption and the FDA has not approved the use for diagnostic, therapeutic, or medical purposes.
We recommend you review our Terms of Service if you have questions about product use.
